OKYO Pharma LimitedNASDAQ: OKYO

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

· Issued by OKYO Pharma Limited via GlobeNewswire

Summary by 6ix AI

OKYO Pharma Limited, a clinical-stage drug developer working on treatments for neuropathic corneal pain (nerve-related pain in the clear front surface of the eye) and diseases of the front of the eye, will take part in the BTIG Biotechnology Conference 2026, held virtually on July 28-29, 2026.

Key details

  • Chief Executive Officer Robert J. Dempsey, Chief Financial Officer Keeren Shah and Chief Medical Officer Flavio Mantelli MD, PhD will represent the company.
  • Investors can request one-on-one meetings with management through their BTIG representative.

6ix AI wrote this summary from the release below and checked it against the release.

LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026.

Company Participation: Robert J. Dempsey, Chief Executive Officer, Keeren Shah, Chief Financial Officer, Flavio Mantelli MD, PhD, Chief Medical Officer

Date/Time: July 28-29, 2026

Location: Virtual

1:1 Meetings: schedule a one-on-one meeting with management by contacting your BTIG representative

About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: [email protected]

OKYO Pharma Limited on 6ix

Story so far

Earlier from OKYO Pharma

Later from OKYO Pharma

All OKYO Pharma news releases